Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan;
Anticancer Res. 2024 Oct;44(10):4551-4559. doi: 10.21873/anticanres.17284.
BACKGROUND/AIM: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver carcinoma, characterized by the unequivocal presence of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). However, its clinicopathological characteristics have not yet been thoroughly elucidated. In particular, cholangiolocellular carcinoma (CLC) was classified as a subtype of cHCC-CCA according to the 2010 World Health Organization (WHO) classification. However, according to the 2019 WHO classification, tumors displaying histological features consistent with CLC but lacking evidence of hepatocellular differentiation should be regarded as a distinct subtype of iCCA. Nevertheless, there may be notable differences in prognosis between CLC and iCCA, indicating the necessity for refining the classification when devising clinical treatment strategies. This study aimed to determine the clinicopathological features and prognostic factors of cHCC-CCAs following radical resection.
Between January 2010 and September 2020, based on the 2010 WHO classification, we retrospectively studied the clinicopathological features and prognoses of patients with cHCC-CCAs in relation to the pathological dominant classification. The patients were classified according to the pathological dominant components of cHCC-CCA as HCC-dominant (HCC-D), iCCA-dominant (iCCA-D), or CLC-dominant (CLC-D).
Data of 55 patients who underwent primary radical hepatectomy for cHCC-CCA were analyzed. The prevalences of each dominant classification were HCC-D, 21 (38.2%); iCCA-D, 11 (20.0%); and CLC-D, 23 (41.8%). Multivariate analysis showed that dominant classification was an independent risk factor for recurrence and cancer-specific survival (CSS).
The dominant classification of cHCC-CCA has the potential to predict recurrence and CSS.
背景/目的:混合细胞型肝癌(cHCC-CCA)是一种罕见的原发性肝癌亚型,其特征为明确存在肝细胞癌(HCC)和肝内胆管癌(iCCA)。然而,其临床病理特征尚未得到充分阐明。特别是,胆管细胞癌(CLC)根据 2010 年世界卫生组织(WHO)分类被归类为 cHCC-CCA 的一个亚型。然而,根据 2019 年 WHO 分类,显示与 CLC 组织学特征一致但缺乏肝细胞分化证据的肿瘤应被视为 iCCA 的一个独特亚型。然而,CLC 和 iCCA 之间可能存在显著的预后差异,这表明在制定临床治疗策略时需要对分类进行细化。本研究旨在确定根治性切除术后 cHCC-CCAs 的临床病理特征和预后因素。
基于 2010 年 WHO 分类,我们回顾性研究了 2010 年 1 月至 2020 年 9 月间接受根治性肝切除术的 cHCC-CCAs 患者的临床病理特征和预后与病理主导分类的关系。患者根据 cHCC-CCA 的病理主导成分分为 HCC 主导型(HCC-D)、iCCA 主导型(iCCA-D)或 CLC 主导型(CLC-D)。
分析了 55 例接受根治性肝切除术治疗 cHCC-CCA 的患者数据。每种主导分类的患病率分别为 HCC-D(占 38.2%)、iCCA-D(占 20.0%)和 CLC-D(占 41.8%)。多因素分析显示,主导分类是复发和癌症特异性生存(CSS)的独立危险因素。
cHCC-CCA 的主导分类具有预测复发和 CSS 的潜力。